{"url_path":"/sec/gyre/proxy/2026-04-27/000114036126017130","section_key":"body","section_title":"DEFA14A body","topic":"sec","document":{"doc_type":"DEFA14A","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-017130-index.html","accession_number":"0001140361-26-017130","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-017130-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":586,"has_tables":true,"body_markdown":"DEFA14A\n1\nny20063852x4_defa14a.htm\nDEFA14A\n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWashington, D.C. 20549\n\nSCHEDULE 14A\n\nProxy Statement Pursuant to Section 14(a) of the\n\nSecurities Exchange Act of 1934\n\n(Amendment No.  )\n\nFiled by the Registrant\n\n​\n\n​\n\n☒\n\nFiled by a Party other than the Registrant\n\n​\n\n​\n\n ☐\n\nCheck the appropriate box:\n\n ☐\n\nPreliminary Proxy Statement\n\n \n \n \n\n ☐\n\nConfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))\n\n ☐\n\nDefinitive Proxy Statement\n\n \n \n \n \n\n☒\n\nDefinitive Additional Materials\n\n \n \n\n ☐\n\nSoliciting Material under §240.14a-12\n\n \n\nGyre Therapeutics, Inc.\n\n(Name of Registrant as Specified In Its Charter)\n\n(Name of Person(s) Filing Proxy Statement if other than the Registrant)\n\nPayment of Filing Fee (Check all boxes that apply):\n\n☒\n\nNo fee required.\n\n \n \n\n ☐\n\nFee paid previously with preliminary materials.\n\n \n\n ☐\n\nFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.\n\nYour Vote Counts! GYRE THERAPEUTICS, INC. 2026 Annual Meeting Vote by June 9, 2026 11:59 PM ET GYRE THERAPEUTICS, INC. 12770 HIGH\nBLUFF DRIVE SUITE 150 SAN DIEGO, CA 92130 V95075-P51256 You invested in GYRE THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 10, 2026. Get informed before you vote View the Notice and Proxy Statement and\nAnnual Report online OR you can receive a free paper or email copy of the proxy materials by requesting prior to May 27, 2026. If you would like to request a paper or email copy of the proxy materials or materials for future stockholder\nmeetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. There is no charge to\nyou for requesting a copy. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com\nControl # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 10, 2026 10:00 a.m. Pacific Time Virtually at: www.virtualshareholdermeeting.com/GYRE2026 *Please check the\nmeeting materials for any special requirements for meeting attendance.\n\nVote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the more complete proxy materials that\nare available to you on the Internet or by mail. You may view the proxy materials at www.proxyvote.com or easily request a paper copy. We encourage you to access and review all of the important information contained in the proxy materials\nbefore voting. Please follow the instructions on the reverse side to vote on these important matters. Board Recommends Voting Items\n\n1. Election of Class II\nDirectors for terms expiring in 2029. For Nominees: 01) David M. Epstein, Ph.D. 02) Dan Weng, M.D. 2.\nTo approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. For 3. To ratify the appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company’s independent registered\npublic accounting firm for the year ending December 31, 2026. For 4. To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company’s common stock, par value $0.001 per share, upon conversion of the\nCompany’s Series B Convertible Preferred Stock, par value $0.001 per share. For NOTE: Such other business as may properly come before the meeting or any adjournment or postponement thereof."}